The American Academy of Dermatology (AAD) 2023 Annual Meeting took place last month in New Orleans, Louisiana, and The American Journal of Managed Care® was there to cover the latest news—catch up on what you may have missed.
Here are the top 5 stories from the American Academy of Dermatology (AAD) 2023 Annual Meeting, which took place in New Orleans, Louisiana, from March 17 to 21, 2023.
5. Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care
Speakers at AAD 2023 highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.
4. Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability
A pair of posters showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.
3. Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says
A panel assembled at AAD 2023 encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
2. Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early
While melanoma is one of the most aggressive cancers, making early detection crucial for outcomes, because it is visible on the surface, there are opportunities to catch it early, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
1. Experts Herald “Year of the JAK Inhibitor” in Dermatology
A symposium at AAD 2023 convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic dermatitis and vitiligo.
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
AI Dermatology Mobile Apps Have Critical Efficacy, Safety Gaps, Review Says
March 17th 2024This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.
Read More
Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa
March 11th 2024Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Read More
Management of HS Requires Both Coordination, Communication Between Patients and Providers
March 10th 2024Treating pediatric and adult patients with hidradenitis suppurativa (HS) who are in socioeconomically underserved areas can be done through collaboration with the patient, their family, and other clinicians in the field.
Read More